Published in Cochrane Database Syst Rev on January 01, 2012
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12
Adherence to medication. N Engl J Med (2005) 39.77
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 24.72
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) 19.05
Priority actions for the non-communicable disease crisis. Lancet (2011) 15.18
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet (2003) 12.67
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53
Going from evidence to recommendations. BMJ (2008) 7.30
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83
Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet (2008) 5.49
Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol (2009) 5.37
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2011) 5.30
Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev (2011) 4.71
Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation (2005) 4.21
Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet (2007) 4.15
Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol (2004) 4.07
Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med (1992) 3.81
Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke (2003) 3.41
Two decades of progress in preventing vascular disease. Lancet (2002) 3.30
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil (2009) 3.19
WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ (2005) 3.09
Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Heart (2008) 2.98
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med (2010) 2.36
Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J (2002) 2.30
Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension (2009) 2.28
Trends in the prevalence of low risk factor burden for cardiovascular disease among United States adults. Circulation (2009) 1.83
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens (2008) 1.61
The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation (2010) 1.51
Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol (2006) 1.35
An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One (2011) 1.34
Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil (2009) 1.28
The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%. BMJ (2004) 1.20
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich) (2006) 0.91
Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) (2003) 0.85
A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol (2007) 0.84
The Polypill in the prevention of cardiovascular disease. Prev Med (2010) 0.83
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. Int J Clin Pract (2005) 0.81
Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev (2013) 1.25
An economic evaluation of a self-management programme of activity, coping and education for patients with chronic obstructive pulmonary disease. Chron Respir Dis (2015) 0.77
Increased consumption of fruit and vegetables for the primary prevention of cardiovascular diseases. Cochrane Database Syst Rev (2012) 0.76
'Mediterranean' dietary pattern for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2012) 0.75
Selenium supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2012) 0.75
Cochrane corner: does increasing intake of dietary fibre help prevent cardiovascular disease? Heart (2016) 0.75
Cochrane Corner: are there benefits of using web-based interventions in the secondary prevention of coronary heart disease? Heart (2016) 0.75